...
 Why us?  Why us? please click dropdown
4.8/5 out of 3,500+ reviews
Regulated: CQC Registered | 1-5796078466
  • Verified Content: Approved by the Women’s Health Clinic Clinical Team.
  • Educational Use: This is not a substitute for professional medical advice, diagnosis, or treatment.
  • Clinical Assessment: Individual suitability is determined by a clinician; results may vary.
  • MEDICAL EMERGENCY:

    If you need urgent help, use NHS 111. For a life-threatening emergency, call 999.

 Author  Find more about the author
Dr Farzana Khan

Dr Farzana Khan

Verified

Dr Farzana Khan qualified as an MD from the University of Copenhagen in 2003. She has worked in dermatology and obstetrics & gynaecology across the North of England and completed her MRCGP (CCT, 2013) and the Diploma of the Faculty of Sexual & Reproductive Health (2013). Her clinical focus is vaginal health—including dryness/GSM, sexual function concerns, lichen sclerosus, and comfort or volume changes. She offers careful assessment, discusses medical and conservative options first, and considers selected regenerative or aesthetic treatments where appropriate. Dr Farzana also trains clinicians as a KOL/Trainer with Neauvia, Asclepion Laser, and RegenLab (since 2023). Ongoing CPD includes IMCAS, CCR, ACE and expert training in women’s intimate fillers, PRP, and polynucleotide injectables. Her approach is simple: clear explanations, realistic expectations, and shared decision-making. Authored and medically reviewed by Dr Farzana Khan.

MD MRCGP DFFP
Was this answer helpful?
Rate Dr Farzana's explanation
faq Vaginal Laxity (postnatalmenopause support)

What is a vulvo-vaginal skin booster and can it help support?

A vulvo-vaginal “skin booster” is a low-viscosity injectable (usually hyaluronic acid) placed very superficially to improve hydration and glide at tender entry points. It can ease stinging and small “paper-cut” splits in selected women—especially when genitourinary syndrome of menopause (GSM) is part of the picture—but it does not “tighten” the vagina or correct prolapse or scar geometry. Best used after pelvic floor rehab and GSM care. Educational only. Results vary. Not a cure.

Clinical Context

Who may benefit most? Postnatal or peri-/post-menopausal women describing mild, entry-focused discomfort (vestibular sting, “paper-cut” fissures, unpredictable first penetration) that persists after a high-quality pelvic floor block and well-managed GSM care. Goals are functional: smoother early penetration, fewer micro-tears, improved tampon/speculum comfort and confidence.

Who is unlikely to benefit? Women with prolapse beyond the introitus, a clearly malpositioned perineal scar, or pain dominated by pelvic floor overactivity. Here, targeted assessment (uro-gynae/physio) or scar-aware pathways work better than repeating injectables. Defer procedures with infection, fever, foul discharge, heavy bleeding, visible haematuria, or new post-menopausal bleeding.

Next steps now. Keep a 6–12-week diary (sting 0–10; micro-tears/spotting; air-trapping; tampon/cup stability; ease at first penetration). Optimise moisturiser/lubricant and consider local oestrogen if acceptable. If a booster is trialled, introduce it as a single new step and review at 6–12 weeks before deciding on a short series.

Evidence-Based Approaches

NHS (patient-friendly foundations): Step-by-step pelvic floor exercises and clear advice for managing vaginal dryness after menopause underpin first-line care and reduce reliance on procedures.

NICE menopause guidance (NG23): Recommends vaginal moisturisers/lubricants and considering low-dose local vaginal oestrogen when symptoms affect quality of life; these steps often resolve entry sting without injectables. NICE NG23.

BNF (product monographs): Prescribing details, cautions and application schedules for vaginal oestrogens (useful where GSM drives micro-tears/dyspareunia). BNF – vaginal oestrogens.

MHRA (UK regulator): Guidance on medical devices/medicines, UKCA/CE marking and vigilance supports safe selection and reporting for intimate procedures and products. MHRA – medical devices.

Cochrane Library & PubMed (context): Systematic reviews support pelvic floor muscle training for pelvic floor symptoms and vaginal oestrogen for GSM; evidence for procedure-based intimate treatments remains heterogeneous and short-term. Public abstracts explain GSM physiology (epithelial thinning, pH/microbiome change), clarifying why friction control and local therapies reduce dyspareunia and micro-tears. Cochrane Library · PubMed – GSM overview.